← Back to Screener
enGene Therapeutics Inc. Common Stock (ENGN)
Price$1.78
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-87.90%
Price vs S&P 500 (4W)-79.45%
VGM Score22.87
Market Capitalization$123.93M
All Metrics
Book Value / Share (Quarterly)$4.20
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.55
Price vs S&P 500 (YTD)-90.45%
EPS (TTM)$-2.25
10-Day Avg Trading Volume1.61M
EPS Excl Extra (TTM)$-2.25
EPS (Annual)$-2.29
ROI (Annual)-61.40%
Cash / Share (Quarterly)$4.12
ROA (Last FY)-52.97%
EBITD / Share (TTM)$-2.31
ROE (5Y Avg)-45.63%
Cash Flow / Share (Annual)$-1.94
P/B Ratio0.44x
P/B Ratio (Quarterly)2.38x
Net Income / Employee (Annual)$-2,606,700
Net Interest Coverage (TTM)-2.94x
ROA (TTM)-45.74%
EPS Incl Extra (Annual)$-2.29
Current Ratio (Annual)6.30x
Quick Ratio (Quarterly)11.26x
3-Month Avg Trading Volume1.21M
52-Week Price Return-53.28%
Revenue / Employee (TTM)$0
52-Week High$12.25
EPS Excl Extra (Annual)$-2.29
26-Week Price Return-71.97%
Quick Ratio (Annual)6.09x
13-Week Price Return-81.56%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)11.75x
Enterprise Value$112.24M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.72
3-Month Return Std Dev182.54%
Net Income / Employee (TTM)$-2,720,800
ROE (Last FY)-69.94%
EPS Basic Excl Extra (Annual)$-2.29
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-2.25
ROI (TTM)-50.38%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-81.49%
Year-to-Date Return-79.51%
5-Day Price Return12.80%
EPS Normalized (Annual)$-2.29
ROA (5Y Avg)-57.58%
Month-to-Date Return-74.55%
EBITD / Share (Annual)$-2.40
LT Debt / Equity (Annual)0.09x
ROI (5Y Avg)-40.33%
LT Debt / Equity (Quarterly)0.09x
EPS Basic Excl Extra (TTM)$-2.25
P/B Ratio (Annual)2.20x
Book Value / Share (Annual)$3.22
Price vs S&P 500 (13W)-91.30%
Beta-0.32x
Revenue / Share (TTM)$0.00
ROE (TTM)-55.83%
52-Week Low$1.40
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.33
4.32
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENGNenGene Therapeutics Inc. Common Stock | — | — | D | $1.78 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
enGene Holdings is a clinical-stage biotech company developing localized gene therapies using its proprietary non-viral DDX delivery platform. The company is initially targeting non-muscle invasive bladder cancer (NMIBC) and aims to expand to other high-need diseases through direct delivery to mucosal tissues and organs.